---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-001603"
form_type: "8-K"
ticker: "BIXT"
cik: "0001445815"
company_name: "BIOXYTRAN, INC"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:48:33.324612+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bioxytran publishes preprint on galectin-3's role in ICI resistance and potential enhancement

## Summary
- Preprint reviews theories that galectin-3 contributes to ICI resistance; galectin-3 antagonists may reverse effect.
- 90% of high galectin-3 NSCLC patients failed to respond to ICI after 3 treatments.
- Surface Plasmon Resonance and cryo-EM confirm galectin-3 blocks ICI binding to PD-1 receptor.
- Company also published cancer presentation on galectin antagonists in cancer.
- CEO states findings herald significant shift in cancer treatment paradigms.

## SEC filing metadata
- accession: 0001493152-25-001603
- form_type: 8-K
- ticker: BIXT
- cik: 0001445815
- company_name: BIOXYTRAN, INC
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1445815/000149315225001603/0001493152-25-001603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1445815/000149315225001603/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-001603
- JSON: https://secwatch.observer/filing/0001493152-25-001603.json
- Plain text: https://secwatch.observer/filing/0001493152-25-001603.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.